Cytavis BioPharma GmbH, of Hamburg, Germany, reported that its melanoma candidate, Aviscumine (CY503), may improve survival of patients with refractory stage IV metastatic melanoma. In the Phase II open-label trial, 31 eligible patients with unresectable metastatic melanoma, who had previously failed antineoplastic therapy, received subcutaneous injections of Aviscumine. Three-month progression-free survival was 32.3 percent, and median overall survival was 11 months